Navigation Links
Acute Coronary Events Drop After Italy's Public Smoking Ban
Date:2/14/2008

Analysis shows young people in low socioeconomic areas had greatest reduction

THURSDAY, Feb. 14 (HealthDay News) -- The number of acute coronary events dropped significantly among adults in Rome after Italy banned smoking in public places in 2005, a new report shows.

Researchers in the Italian capital found an 11.2 percent reduction of acute coronary events in persons aged 35 to 64 years and a 7.9 percent reduction in those aged 65 to 74, according to the findings in the Feb. 12 issue of Circulation.

Cigarette sales and the frequency of people smoking also dropped.

"Since coronary heart disease is a leading cause of death in Italy, the reduction observed had enormous public health implications," study co-author Francesco Forastiere, head of the environmental and occupational epidemiology unit of the Rome E. Health Authority, said in a prepared statement. "It will be interesting to see if the effect of the ban is stable over time, and if similar positive health effects can be detected in other places."

The study was the first in Europe to show long-term health benefits of smoking bans in public places.

Researchers looked at city statistics for the five years preceding a 2005 public smoking ban with those from one year after. They identified acute coronary events from hospital discharge reports with a diagnosis of myocardial infarction or unstable angina and from the regional register of causes of deaths with diagnosis of out-of-hospital coronary deaths.

The January 2005 comprehensive smoking ban in Italy included all indoor public places such as offices, retail shops, restaurants, pubs and discos.

Young people living in low socioeconomic areas seemed to have the greatest reduction in acute coronary events after the smoking ban, researchers reported. Those living in lower socioeconomic areas have worse health conditions with more risk factors for heart attack such as obesity, hypertension, diabetes and a higher rate of smoking.

"This implies that a disadvantaged person has a higher probability of being surrounded by smokers at work and in public places unless a smoking ban is in place," Giulia Cesaroni, senior researcher at the Department of Epidemiology in Rome, said in a prepared statement.

The ban also appeared to have changed people's smoking habits. According to the report, the frequency of smoking decreased from 34.9 percent to 30.5 percent in men and from 20.6 percent to 20.4 percent in women. Cigarette sales also decreased 5.5 percent.

However, the smoking ban did not appear to reduce coronary events in those aged 75 to 84.

"The older age group spends more time at home than in the workplace or public businesses," Cesaroni said. "The smoking ban has a greater effect on those of working age and those who spend a lot of their time in public places."

More information

The National Cancer Institute offers has more about how to quit smoking.



-- Kevin McKeever



SOURCE: American Heart Association, news release, Feb. 11, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Acute coronary events decreased after public smoking ban in Italy
2. Hill-Rom Introduces Fashionable, Affordable Bed for Home and Post-Acute Care Patients
3. Physicians Still Hopeful About Desmoteplase for the Treatment of Acute Ischemic Stroke Despite Negative Results
4. Kidney cancer drug attacks a major type of acute myeloid leukemia
5. Answering Bush SOTU Retirement Reform Challenge, Long Term Care Profession Urges Congress to Enact Bold Reform of Long Term and Post Acute Care Delivery Systems
6. Molecules might identify high-risk acute-leukemia patients
7. Engaging 2008 Debate, Key Long Term Care Advocacy Groups Offer New Plan to Strengthen Nations Long Term and Post-Acute Care Delivery System
8. FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
9. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
10. Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
11. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Acute Coronary Events Drop After Italy's Public Smoking Ban
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: